폐경 후 골다공증 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the postmenopausal osteoporosis market size is expected to grow from USD 8.03 billion in 2025 to USD 8.33 billion in 2026 and is forecast to reach USD 9.97 billion by 2031 at 3.68% CAGR over 2026-2031.

This report is Segmented by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs) and More), by Route of Administration (Oral, Intraveous, and More), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores and More). Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Postmenopausal Osteoporosis Market Trends and Insights

Growing Ageing Female Population Base

The number of women aged 50 years and older is projected to climb 30% globally by 2030, driving first-line screening and therapy use. Recent studies in China reveal significant regional variations, with Shanghai reporting osteoporosis prevalence of 12.5% among middle-aged adults, while Sichuan Province demonstrates 19.42% overall prevalence, with 32.1% of postmenopausal women and 6.9% of men over 50 affected. Longer life expectancy positions high-risk women for extended pharmacologic exposure, increasing demand for agents with proven fracture-risk reduction. Consequently, manufacturers are prioritising once-yearly or biannual dosing regimens to align with geriatric adherence needs.

Fracture-Cost Containment Programs by Insurers

US and EU payers intensify post-fracture programs after economic analyses show that treating high-risk patients early saves direct medical costs compared with managing subsequent fractures. Mexican modelling demonstrated that romosozumab can reduce lifetime costs by USD 51,363 per patient while improving outcomes relative to teriparatide. Belgium followed with favourable health-economic findings supporting reimbursement for anabolic treatment in very high-risk postmenopausal women. Insurers therefore steer formularies toward injectable therapies showing 92.5% adherence versus 63.5% for oral alendronate.

Safety Concerns around Long-Term Bisphosphonate Use

Emerging evidence links extended bisphosphonate courses with atypical femoral fractures and osteonecrosis of the jaw, prompting clinicians to opt for drug holidays after 3-5 years. Awareness campaigns in the US and EU shifted 12-month persistence from 54% in 2020 to 47% in 2024 as cautious patients discontinued therapy, dampening sales. Regulatory agencies now require class-wide labelling updates describing rare fracture risks. These safety dialogues accelerate physician adoption of injectables that deliver comparable or superior BMD gains without prolonged skeletal retention. Nevertheless, payers weigh the higher acquisition cost of biologics against long-term fracture avoidance benefits.

Other drivers and restraints analyzed in the detailed report include:

1. Bisphosphonate Patent Expiries Boosting Generics
2. Launch of Anabolic Agents with Superior BMD Efficacy
3. Declining DXA Scanner Reimbursement in Europe

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Bisphosphonates commanded 46.68% of the osteoporosis drugs market share in 2025, buoyed by decades of clinician familiarity and low pricing. However, the osteoporosis drugs market size for RANKL inhibitors is projected to expand as biosimilar denosumab variants roll out worldwide. Sandoz introduced Wyost and Jubbonti in May 2025 in the US, and Samsung Bioepis, Celltrion and Teva will follow through 2026. First-to-market biosimilars launched at price discounts of 20-30%, accelerating adoption in cost-sensitive health systems.

Sequential anabolic-antiresorptive therapy is becoming standard in very high-risk cohorts, sustaining demand for both classes. Parathyroid hormone analogs gain renewed momentum after NICE endorsed abaloparatide, and experts predict double-digit uptake in Europe once reimbursement cascades through other markets. SERMs and calcitonin maintain niche usage among patients contra-indicated for frontline agents. Generic pipelines remain active across all small-molecule classes, and reformulation strategies such as effervescent tablets aim to retain market share against low-cost copies. Overall, innovation and biosimilar economics intertwine to create a two-tier competitive field where value-based pricing dominates purchasing.

Complete Report Scope:

• By Treatment
  • Vitamin D
  • Bisphosphonates
  • Hormone Replacement Therapy
  • Parathyroid Hormone Therapy
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 37.28% of 2025 revenue for the osteoporosis drugs market. Broad insurance coverage and rapid adoption of novel agents underpin leadership, while the FDA's clearance of digital therapeutic Osteoboost exemplifies the region's openness to breakthrough solutions. Biosimilar pressure escalates after February 2025, yet Amgen's Prolia still posted 10% sales growth in Q1 2025 pre-erosion, signalling resilience through brand loyalty programs. Policy moves such as CMS removing prior-authorisation hurdles on select bone stimulators further smooth treatment pathways .

Europe shows steady, value-driven uptake of biosimilars after EMA approvals of Wyost, Jubbonti, Stoboclo and Osenvelt through 2024-2025. NICE's economic endorsement of abaloparatide in England set a precedent for wider EU funding, covering 14,000 high-risk women in its first year. Nonetheless, shrinking DXA reimbursement narrows diagnostic capacity, prompting Italian experts to petition AIFA for algorithm-based fracture-risk assessment upgrades. Health ministries weigh mobile scanning vans and AI-enhanced CT analytics to mitigate bottlenecks.

Asia-Pacific posts the fastest 6.41% CAGR as shifting demographics swell the patient base; prevalence already affects up to 30% of women over 40 in developed regional economies. Multinationals pursue local licensing; Radius granted Pharmanovia rights to abaloparatide for China and ASEAN markets in March 2025, aiming to leverage escalating fracture rates. Regional guidelines increasingly acknowledge ethnicity-specific BMD norms to prevent misclassification, highlighting the need for device calibration research.

List of Companies Covered in this Report:

1. Amgen
2. Eli Lilly and Company
3. Pfizer
4. Procter & Gamble
5. Novartis
6. Clonz Biotech
7. Ligand Pharmaceuticals
8. Merck
9. BiologicsMD
10. Enteris BioPharma
11. Oncobiologics
12. Abbvie

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increase in Geriatric Population
  • 4.2.2 Investment by Market Players and Thereby Strong Pipeline
• 4.3 Market Restraints
  • 4.3.1 Low Awarenss about Postmenopause Osteoporosis
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Treatment
  • 5.1.1 Vitamin D
  • 5.1.2 Bisphosphonates
  • 5.1.3 Hormone Replacement Therapy
  • 5.1.4 Parathyroid Hormone Therapy
  • 5.1.5 Others
• 5.2 By Distribution Channel
  • 5.2.1 Hospital Pharmacies
  • 5.2.2 Retail Pharmacies
  • 5.2.3 Online Pharmacies
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Amgen Inc.
  • 6.1.2 Eli Lilly and CO.
  • 6.1.3 Pfizer Inc.
  • 6.1.4 Proctor & Gamble Co.
  • 6.1.5 Novartis International AG
  • 6.1.6 Clonz Biotech
  • 6.1.7 Ligand Pharmaceuticals Incorporated.
  • 6.1.8 Merck & Co., Inc
  • 6.1.9 BiologicsMD
  • 6.1.10 Enteris BioPharma
  • 6.1.11 Oncobiologics, Inc.
  • 6.1.12 AbbVie (Allergan plc)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS